Opportunities for using in silico‐based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors is a research paper published in British Journal of Clinical Pharmacology (2020). On theSindex it has a DataRank of 0. It has been cited 35 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Intramural NIH HHS
Grant: Z01 SC006537
Intramural NIH HHS
Grant: ZIC SC006537
FWCI
1.90
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study
Additional file 1 of A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study